At baseline, the mutant variants were detected in half of the CRC patients (i.e., VAF > LOB, 9/18): one out of fourstage II, one out of one stage III and one out of one stage IV patients with BRAF and three out of four stage II, two out of three stage III and one out of one stage IV patients with KRAS variants. Here, KRAS is linked to colorectal carcinoma.